Compare TMDX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | HCM |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2019 | 2015 |
| Metric | TMDX | HCM |
|---|---|---|
| Price | $67.09 | $13.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $98.73 | $21.14 |
| AVG Volume (30 Days) | ★ 807.7K | 34.5K |
| Earning Date | 11-05-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $605,494,000.00 | N/A |
| Revenue This Year | $22.50 | $14.19 |
| Revenue Next Year | $17.97 | $11.70 |
| P/E Ratio | $109.77 | ★ $5.49 |
| Revenue Growth | ★ 37.13 | N/A |
| 52 Week Low | $60.11 | $9.77 |
| 52 Week High | $156.00 | $16.33 |
| Indicator | TMDX | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 41.56 |
| Support Level | $66.77 | $13.00 |
| Resistance Level | $71.14 | $15.10 |
| Average True Range (ATR) | 3.64 | 0.33 |
| MACD | -0.33 | -0.14 |
| Stochastic Oscillator | 19.84 | 4.95 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.